Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) major shareholder Ventures Fund V. Gener Flagship sold 347,870 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $6.57, for a total transaction of $2,285,505.90. Following the completion of the sale, the insider now owns 1,447,791 shares of the company’s stock, valued at $9,511,986.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Sana Biotechnology Stock Performance
NASDAQ:SANA traded up $0.04 during midday trading on Friday, reaching $6.28. 1,094,503 shares of the stock traded hands, compared to its average volume of 1,201,326. Sana Biotechnology, Inc. has a 12 month low of $2.99 and a 12 month high of $9.55. The stock has a market capitalization of $1.20 billion, a P/E ratio of -3.64 and a beta of 0.71. The company has a fifty day moving average of $4.98 and a 200 day moving average of $4.51.
Sana Biotechnology (NASDAQ:SANA – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. On average, analysts predict that Sana Biotechnology, Inc. will post -1.49 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP bought a new position in Sana Biotechnology in the 3rd quarter worth $652,000. Point72 Hong Kong Ltd bought a new position in Sana Biotechnology in the 3rd quarter worth $58,000. Barclays PLC grew its position in shares of Sana Biotechnology by 904.3% in the 3rd quarter. Barclays PLC now owns 293,227 shares of the company’s stock worth $1,759,000 after buying an additional 264,030 shares during the period. Clarius Group LLC grew its position in shares of Sana Biotechnology by 274.6% in the 4th quarter. Clarius Group LLC now owns 46,825 shares of the company’s stock worth $185,000 after buying an additional 34,325 shares during the period. Finally, Bridgefront Capital LLC purchased a new stake in shares of Sana Biotechnology in the 3rd quarter worth about $63,000. 67.12% of the stock is currently owned by institutional investors.
About Sana Biotechnology
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
- Get a free copy of the StockNews.com research report on Sana Biotechnology (SANA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.